Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Short Interest Up 310.3% in December

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 693,000 shares, a growth of 310.3% from the December 15th total of 168,900 shares. Based on an average daily trading volume, of 3,270,000 shares, the days-to-cover ratio is presently 0.2 days.

Quoin Pharmaceuticals Price Performance

Quoin Pharmaceuticals stock traded up $0.00 during mid-day trading on Tuesday, hitting $0.57. 217,596 shares of the company were exchanged, compared to its average volume of 520,549. Quoin Pharmaceuticals has a 12-month low of $0.43 and a 12-month high of $6.18. The company has a market capitalization of $2.89 million, a P/E ratio of -0.14 and a beta of 1.75. The business’s 50 day simple moving average is $0.64 and its two-hundred day simple moving average is $0.63.

Insider Transactions at Quoin Pharmaceuticals

In other news, Director Anthony James Culverwell purchased 100,000 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were bought at an average price of $0.45 per share, with a total value of $45,000.00. Following the completion of the transaction, the director now directly owns 100,317 shares in the company, valued at approximately $45,142.65. This represents a 31,545.74 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Gordon Dunn bought 122,221 shares of the stock in a transaction dated Monday, December 23rd. The shares were acquired at an average price of $0.45 per share, for a total transaction of $54,999.45. Following the completion of the transaction, the chief financial officer now owns 151,077 shares of the company’s stock, valued at approximately $67,984.65. The trade was a 423.55 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 777,777 shares of company stock worth $350,000. 3.70% of the stock is currently owned by insiders.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.